Twist Bioscience raises FY24 revenue view to $300M-$304M from $288M-$293M

Consensus $293.1M. SynBio revenue is expected to be in the range of $118 million to $120 million compared to the previous estimate of $114 million to $117 million, indicating year over year growth of 20 to 22 percent. NGS revenue is expected to be in the range of $162 million to $164 million compared to the previous estimate of $150 million to $152 million, indicating year over year growth of 31 to 33 percent. Biopharma revenue is expected to be approximately $20 million compared to the previous estimate of approximately $24 million, indicating year over year decrease of approximately 13 percent.